High-Dose Tigecycline in Elderly Patients with Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii in Intensive Care Unit

References

• Kalanuria AA, Ziai W, Zai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care. 2014;18(2):208. doi:10.1186/cc1377525029020
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care. 2016;20(1):221. doi:10.1186/s13054-016-1392-427417949
   PubMed Web of Science ®Google Scholar
• Goel V, Hogade SA, Karadesai S. Ventilator associated pneumonia in a medical intensive care unit: microbial aetiology, susceptibility patterns of isolated microorganisms and outcome. Indian J Anaesth. 2012;56(6):558–562. doi:10.4103/0019-5049.10457523325941
   PubMedGoogle Scholar
• Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–1263. doi:10.1086/52919818444865
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 2015;41(12):2057–2075. doi:10.1007/s00134-015-4079-426438224
   PubMed Web of Science ®Google Scholar
• Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331–336. doi:10.1016/j.diagmicrobio.2012.12.00423357291
   PubMed Web of Science ®Google Scholar
• Shin JA, Chang YS, Kim HJ, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med J. 2012;53(5):974–984. doi:10.3349/ymj.2012.53.5.97422869481
   PubMed Web of Science ®Google Scholar
• Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J. 2017;50(3). doi:10.1183/13993003.00582-2017
   Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–61e111. doi:10.1093/cid/ciw35327418577
   PubMed Web of Science ®Google Scholar
• Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-131478103
   PubMed Web of Science ®Google Scholar
• Geng TT, Xu X, Huang M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study. Medicine (Baltimore). 2018;97(8):e9961. doi:10.1097/MD.000000000000996129465589
   PubMed Web of Science ®Google Scholar
• Xu L, Wang YL, Du S, Chen L, Long LH, Wu Y. Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia. Chemotherapy. 2016;61(6):323–330. doi:10.1159/00044542527144279
   PubMed Web of Science ®Google Scholar
• Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018;73(suppl_3):iii2–2iii78. doi:10.1093/jac/dky02729514274
   PubMed Web of Science ®Google Scholar
• Zha L, Oho AUID, Pan L, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1049–1064. doi:10.1007/s12325-020-01235-y32006240
   PubMed Web of Science ®Google Scholar
• Giuliano C, Patel CR, Kale-Pradhan PB. A guide to bacterial culture identification and results interpretation. P T. 2019;44(4):192–200.30930604
   PubMedGoogle Scholar
• Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis. Medicine (Baltimore). 2020;99(10):e19466. doi:10.1097/MD.000000000001946632150105
   PubMed Web of Science ®Google Scholar
• American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416. doi:10.1164/rccm.200405-644ST15699079
   PubMed Web of Science ®Google Scholar
• Roffman CE, Buchanan J, Allison GT. Charlson comorbidities index. J Physiother. 2016;62(3):171. doi:10.1016/j.jphys.2016.05.00827298055
   PubMed Web of Science ®Google Scholar
• Man SY, Chan KM, Wong FY, et al. Evaluation of the performance of a modified Acute Physiology and Chronic Health Evaluation (APACHE II) scoring system for critically ill patients in emergency departments in Hong Kong. Resuscitation. 2007;74(2):259–265. doi:10.1016/j.resuscitation.2006.12.01517379379
   PubMed Web of Science ®Google Scholar
• Hammond JM, Potgieter PD. Source of infection in nosocomial pneumonia. Lancet. 1993;341(8856):1358.
   Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377. doi:10.1007/s00134-017-4683-628101605
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Jones RN. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005–2009). Diagn Microbiol Infect Dis. 2011;69(2):223–227. doi:10.1016/j.diagmicrobio.2010.10.02021251571
   PubMed Web of Science ®Google Scholar
• Wang H, Song Y, Wang M, Ni Y, Ma Y, Jiankang R. Expert consensus on operating procedures for tigecycline in vitro susceptibility testing. Chin J Lab Med. 2013;7(36):584–587. doi:10.3760/cma.j.issn.1009-9158.2009.11.002
   Google Scholar
• Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008;46(7):1121–1122. doi:10.1086/52886718444833
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar
• Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis. 2007;45(9):1179–1181. doi:10.1086/52228717918079
   PubMed Web of Science ®Google Scholar
• Ren Y, Ma G, Peng L, Ren Y, Zhang F. Active screening of multi-drug resistant bacteria effectively prevent and control the potential infections. Cell Biochem Biophys. 2015;71(2):1235–1238. doi:10.1007/s12013-014-0333-625416582
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, Phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285–295. doi:10.1016/S1473-3099(17)30747-829254862
   PubMed Web of Science ®Google Scholar
• Ye JJ, Lin HS, Yeh CF, et al. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. BMC Infect Dis. 2016;16(1):374. doi:10.1186/s12879-016-1717-627496018
   PubMed Web of Science ®Google Scholar
• Sun JW, Rogers JR, Her Q, et al. Validation of the combined comorbidity index of charlson and elixhauser to predict 30-day mortality across ICD-9 and ICD-10. Med Care. 2018;56(9):812. doi:10.1097/MLR.0000000000000954
   Web of Science ®Google Scholar
• Despotovic A, Milosevic B, Milosevic I, et al. Hospital-acquired infections in the adult intensive care unit-Epidemiology, antimicrobial resistance patterns, and risk factors for acquisition and mortality. Am J Infect Control. 2020:1–5. doi:10.1016/j.ajic.2020.01.00931882063
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11(11):834–844. doi:10.1016/S1473-3099(11)70177-321784708
   PubMed Web of Science ®Google Scholar
• Bai XR, Liu JM, Jiang DC, Yan SY. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies. J Chemother. 2018;1–7. doi:10.1080/1120009X.2018.1425279
   Web of Science ®Google Scholar
• Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44(1):1–7. doi:10.1016/j.ijantimicag.2014.01.00624602499
   PubMed Web of Science ®Google Scholar
• Jung SY, Lee SH, Lee SY, et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care. 2017;21(1):319. doi:10.1186/s13054-017-1916-629262831
   PubMed Web of Science ®Google Scholar
• Lee NY, Wang CL, Chuang YC, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy. 2007;27(11):1506–1511. doi:10.1592/phco.27.11.150617963460
   PubMed Web of Science ®Google Scholar
• Mei H, Yang T, Wang J, Wang R, Cai Y. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis. J Antimicrob Chemother. 2019;74(12):3423–3431. doi:10.1093/jac/dkz33731377765
   PubMed Web of Science ®Google Scholar
• Li J, Fu Y, Zhang J, et al. Efficacy of tigecycline monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii sequence type 2 in Heilongjiang Province. Ann Palliat Med. 2019;8(5):651–659. doi:10.21037/apm.2019.11.0631865726
   PubMed Web of Science ®Google Scholar
• Tuon FF, Graf ME, Merlini A, et al. Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. 2017;21(1):1–6. doi:10.1016/j.bjid.2016.09.00827821248
   PubMed Web of Science ®Google Scholar
• He H, Zheng Y, Sun B, Tang X, Wang R, Tong Z. Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii. J Thorac Dis. 2016;8(10):2784–2792. doi:10.21037/jtd.2016.10.2927867554
   PubMed Web of Science ®Google Scholar
• Amat T, Gutierrez-Pizarraya A, Machuca I, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2017:1–5. doi:10.1016/j.cmi.2017.09.016
   Web of Science ®Google Scholar
• Qin Y, Zhang J, Wu L, Zhang D, Fu L, Xue X. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii. Int J Clin Pharmacol Ther. 2018;56:120. doi:10.5414/CP20310229319497
   PubMed Web of Science ®Google Scholar
• Liu B, Bai Y, Liu Y, et al. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. J Chemother. 2015;27(5):271–276. doi:10.1179/1973947814Y.000000020325068186
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56(2):1065–1072. doi:10.1128/AAC.01615-1022143524
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the boston collaborative drug surveillance program. J Am Geriatr Soc. 1979;27(1):20–22. doi:10.1111/j.1532-5415.1979.tb01715.x759470
   PubMed Web of Science ®Google Scholar
• Routsi C, Kokkoris S, Douka E, Ekonomidou F, Karaiskos I, Giamarellou H. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2015;45(1):90–93. doi:10.1016/j.ijantimicag.2014.07.014
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015;59(3):1650–1655. doi:10.1128/AAC.04305-1425547356
   PubMed Web of Science ®Google Scholar